Company
Headquarters: Tianjin, China
Employees: 4,840
CN¥21.94 Billion
CNY as of July 1, 2024
US$3.02 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, together with its subsidiaries, manufactures and sells Chinese herbal medicines, proprietary Chinese medicines, chemical raw materials and preparations, and nutritional and health products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals, as well as offers pharmaceutical consultancy services. In addition, it provides logistics, stocks, equipment installation, and medicine processing services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products and biological products under other brands from distributors and sells these to other wholesalers. Tianjin Zhong Xin Pharmaceutical Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Tianjin Zhong Xin Pharmaceutical Group Corp Ltd has the following listings and related stock indices.
Stock: SSE: 600329 wb_incandescent
Stock: XSTU: 2TZ wb_incandescent
Stock: SGX: T14 wb_incandescent